Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's "Biotech-In-A-Pharma" R&D Model Makes Progress

Executive Summary

Since the mid-2000s, GlaxoSmithKline has been working to rejuvenate its R&D organization, which it believed wasn't sufficiently productive. Industry watchers are gauging progress closely, particularly as the cornerstone of its new approach, the division of GSK's drug discovery operations into nearly 40 specialized and idiosyncratic Drug Performance Units, or DPUs, approaches milestone deadlines in 2011, and as the rest of the industry also struggles with R&D productivity.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS052882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel